Funding of US biomedical research, 2003-2008

JAMA

Volumn 303, Issue 2, 2010, Pages 137-143

  Dorsey, E Ray ^a   De Roulet, Jason ^e   Thompson, Joel P ^f   Reminick, Jason I ^b,c   Thai, Ashley ^g   White Stellato, Zachary ^d   Beck, Christopher A ^d   George, Benjamin P ^b   Moses III, Hamilton ^g,h  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Alerion Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; PRIORITY JOURNAL; UNITED STATES;

EID: 73949089207     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1987     Document Type: Article

References (33)

1. Moses H III, Dorsey ER, Matheson DH, Thier SO. Financial anatomy of biomedical research. JAMA. 2005; 294(11):1333-1342.
2. Blumenthal D. Stimulating the adoption of health information technology. N Engl J Med. 2009;360 (15):1477-1479.
3. National Institutes of Health Office of Budget. Biomedical Research and Development Price Index (BRDPI). National Institutes of Health Web site. http: //officeofbudget.od.nih.gov/gbiPriceIndexes.html. 2009. Accessed April 13, 2009.
4. National Institutes of Health Office of Budget. Biomedical Research and Development Price Index: fiscal year 2008 update and projections for FY 2009-FY 2014. National Institutes of Health Web site. http: //officeofbudget.od.nih.gov/ pdfs/FY09 /BRDPI-Proj-Feb-2009-final.pdf. February 3, 2009. Accessed November 23, 2009.
5. National Science Foundation Division of Science Resource Statistics. Federal funds for research and development: fiscal years 2005-07. Publication No. 09-300. http://www.nsf.gov/statistics/nsf09300/pdf /nsf09300.pdf. Accessed April 13, 2009.
6. Funding: glossary & acronym list. US Department of Health and Human Services Web site. http://grants .nih.gov/Grants/glossary.htm. Accessed November 23, 2009.
7. Centers for Medicare & Medicaid Services. National Health Expenditure Data. Centers for Medicare & Medicaid Services Web site. http://www.cms .hhs.gov/NationalHealthExpendData/. Accessed April 13, 2009.
8. Centers for Medicare & Medicaid Services. Summary of Benchmark Changes (NHEA) 2004. Centers for Medicare & Medicaid Services Web site. http: //www.cms.hhs.gov/NationalHealthExpendData /downloads/benchmark.pdf. Accessed April 13, 2009.
9. Pharmaceutical Industry Profile 2009. Washington, DC: PhRMA; 2009.
10. Biopharmaceutical industry research & development tops $49 billion in 2004. Burrill & Co Web site. http://www.burrillandco.com/news- 227.html. March 17, 2005. Accessed April 13, 2009.
11. Biopharmaceutical industry research & development tops $51 billion in 2005. Burrill & Co Web site. http://www.burrillandco.com/news- 213.html. March 7, 2006. Accessed April 13, 2009.
12. Biopharmaceutical industry research & development tops $55 billion in 2006. Burrill & Co Web site. http://www.burrillandco.com/news- 197.html. February 12, 2007. Accessed April 13, 2009.
13. R&D spending by US biopharmaceutical companies increases 3 percent in 2008. Burrill & Co Web site. http://www.burrillandco.com/news-359.html. March 10, 2009. Accessed April 13, 2009.
14. Filings and forms. US Securities and Exchange Commission Web site. http://www.sec.gov/edgar .shtml. Accessed April 13, 2009.
15. Drugs: NME drug and new biologic approvals. US Food and Drug Administration Web site. http: //www.fda.gov/Drugs/DevelopmentApprovalProcess /HowDrugsareDevelopedandApproved/Drugand BiologicApprovalReports/ucm121136.htm. Accessed April 13, 2009.
16. Medical devices: PMA approvals. US Food and Drug Administration Web site. http://www.fda.gov /MedicalDevices/ProductsandMedicalProcedures /DeviceApprovalsandClearances/PMAApprovals /default.htm. Accessed April 13, 2009.
17. National Science Foundation Division of Science Resources Statistics. Academic research and development expenditures: fiscal year 2007. Publication No. 09-303. March 2009. http://www.nsf.gov/statistics /nsf09303/pdf/nsf09303. pdf. Accessed April 13, 2009.
18. Reports on federal funding for health services research: 2004-2008. Coalition for Health Services ResearchWebsite. http://www.chsr.org/reports.htm. Accessed August 18, 2009.
19. Robert Wood Johnson Foundation. Annual reports, 2003-2008. Robert Wood Johnson Foundation Web site. http://www.rwjf.org/about /annualreportlist.jsp. Accessed August 24, 2009.
20. National economic accounts. Bureau of Economic AnalysisWebsite. http://www.bea.gov/national /index.htm. Accessed April 13, 2009.
21. Goldston D. A delicate balance. Nature. 2008; 453(7197):838.
22. Danzon PM. Economics of the pharmaceutical industry. National Bureau of Economic Research Web site. http://www.nber.org/cgi-bin/printit?uri=/reporter /fall06/danzon.html. Accessed September 9, 2009.
23. Pisano GP. Science Business: The Promise, the Reality, and the Future of Biotech. Boston, MA: Harvard Business Press; 2006:122-124.
24. Butler D. Transitional research: crossing the valley of death. Nature. 2008;453(7197):840-842.
25. Schweitzer SO. Pharmaceutical Economics and Policy. New York, NY: Oxford University Press; 2007.
26. Guide to R&D funding data-international comparisons. American Association for the Advancement of Science Web site. http://www.aaas.org/spp /rd/guiintl.htm. Accessed August 18, 2009.
27. Wilensky GR. Developing a center for comparative effectiveness information. Health Aff (Millwood). 2006;25(6):w572-w585.
28. Wood AJ. A proposal for radical changes in the drug-approval process. N Engl J Med. 2006;355 (6):618-623.
29. Drews J. Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov. 2006; 5(8):635-640.
30. Fitzgerald GA. Drugs, industry, and academia. Science. 2008;320(5883):1563.
31. Anderson GF, Reinhardt UE, Hussey PS, Petrosyan V. It's the price, stupid: why the United States is so different from other countries. Health Aff (Millwood). 2003;22(3):89-105.
32. Newhouse JP. Why is there a quality chasm? Health Aff (Millwood). 2002;21(4):13-25.
33. Hoffman A, Pearson SD. "Marginal medicine": targeting comparative effectiveness research to reduce waste. Health Aff (Millwood). 2009;28(4): w710-w718.